Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial,Alzheimer's & Dementia

当前位置： X-MOL 学术 › Alzheimers Dement. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial
Alzheimer's & Dementia ( IF 13.0 ) Pub Date : 2019-10-03 , DOI: 10.1016/j.jalz.2019.06.4946
Stephan Ehrhardt ₁ , Anton P Porsteinsson ₂ , Cynthia A Munro ₃ , Paul B Rosenberg ₃ , Bruce G Pollock ₄ , Davangere P Devanand ₅ , Jacobo Mintzer ₆ , Tarek K Rajji ₄ , Zahinoor Ismail ₇ , Lon S Schneider ₈ , Sheriza N Baksh ₁ , Lea T Drye ₁ , Dimitri Avramopoulos ₉ , David M Shade ₁ , Constantine G Lyketsos ₃ ,

Affiliation

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Division of Geriatric Psychiatry and Neuropsychiatry, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine and Johns Hopkins Bayview Medical Center, Baltimore, MD, USA.
Campbell Family Research Institute and Division of Adult Neurodevelopment and Geriatric Psychiatry, CAMH, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Division of Geriatric Psychiatry, New York State Psychiatric Institute and College of Physicians and Surgeons of Columbia University, New York, NY, USA.
Roper St. Francis Research and Innovation Center, Charleston, SC, USA; Medical University of South Carolina, College of Health Professionals and Ralph H Johnson VA Medical Center, Charleston, SC, USA.
Department of Psychiatry, Hotchkiss Brain Institute and O'Brien Institute for Public Health, University of Calgary, Calgary, AB, Canada; Department of Clinical Neurosciences, Hotchkiss Brain Institute and O'Brien Institute for Public Health, University of Calgary, Calgary, AB, Canada; Department of Community Health Sciences, Hotchkiss Brain Institute and O'Brien Institute for Public Health, University of Calgary, Calgary, AB, Canada.
Departments of Psychiatry and the Behavioral Sciences and Neurology, University of Southern California Keck School of Medicine and the University of Southern California Leonard Davis School of Gerontology, Los Angeles, CA, USA; Department of Neurology, University of Southern California Keck School of Medicine and the University of Southern California Leonard Davis School of Gerontology, Los Angeles, CA, USA.
Department of Psychiatry and Behavioral Sciences, Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Alzheimer's disease (AD) is a disabling, common cause of dementia, and agitation is one of the most common and distressing symptoms for patients with AD. Escitalopram for agitation in Alzheimer's disease (S‐CitAD) tests a novel, clinically derived therapeutic approach to treat agitation in patients with AD.

中文翻译：

艾司西酞普兰治疗阿尔茨海默病的躁动 (S-CitAD)：研究者发起的随机、对照、多中心临床试验的方法和设计

阿尔茨海默病 (AD) 是痴呆症的常见致残原因，而躁动是 AD 患者最常见和最令人痛苦的症状之一。艾司西酞普兰治疗阿尔茨海默病的躁动 (S-CitAD) 测试了一种新的临床衍生治疗方法来治疗 AD 患者的躁动。

更新日期：2019-10-03

点击分享查看原文

点击收藏

阅读更多本刊最新论文